Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048350830> ?p ?o ?g. }
- W3048350830 endingPage "1504" @default.
- W3048350830 startingPage "1504" @default.
- W3048350830 abstract "The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure.To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography results to older adults who did not have cognitive impairment.This observational study included participants who were screening for a multisite randomized clinical trial that began on February 28, 2014, and is anticipated to be completed in 2022. Participants aged 65 to 85 years who had no known cognitive impairments underwent an amyloid positron emission tomography scan and learned their result from an investigator who used a protocol-specified process that included prescan education and psychological assessments. This report compares participants with elevated amyloid levels with at least 1 available outcome measure with participants who did not have elevated amyloid levels who enrolled in an observational cohort study and received further evaluations. Data were collected from April 2014 to December 2017 and analyzed from March 2019 to October 2019.A personal biomarker result described as either an elevated or not elevated amyloid level.To assess the immediate and short-term psychological outcome of disclosure, the following validated measures were used: the Geriatric Depression Scale, the state items from the State-Trait Anxiety Inventory, and the Columbia Suicide Severity Rating Scale, as well as the Concerns About AD Scale and the Future Time Perspective Scale to assess changes in participants' perceived risk for AD and perceived remaining life span, respectively.A total of 1167 participants with elevated amyloid levels and 538 participants with not elevated amyloid levels were included. Participants had a mean (SD) age of 71.5 (4.7) years, 1025 (60.1%) were women, and most were white (1611 [94.5%]) and non-Latino (1638 [96.1%]). Compared with participants who learned that they had a not elevated amyloid result, individuals who learned of an elevated amyloid result were no more likely to experience short-term increases in depression (mean [SD] change in the Geriatric Depression Scale score, 0.02 [1.3] vs 0.04 [1.3]; P = .90), anxiety (mean [SD] change in State-Trait Anxiety Inventory score, -0.02 [3.2] vs -0.15 [3.0]; P = .65), or suicidality (mean [SD] change in the Columbia Suicide Severity Rating Scale score, 0.0 [0.4] vs -0.01 [0.5]; P = .67). Participants with elevated amyloid levels had increased Concern About AD scores (raw change in scores: elevated amyloid group, 0.8 [3.9]; not elevated amyloid group, -0.4 [3.8]; P < .001). Participants with not elevated amyloid levels experienced a slight increase in Future Time Perspective score(mean [SD] score, 1.15 [7.4] points; P < .001); there was no change in time perspective among those receiving an elevated amyloid result (mean [SD] score, 0.33 [7.8] points).In this observational preclinical AD study, participants who learned they had elevated amyloid levels did not experience short-term negative psychological sequelae compared with persons who learned they did not have elevated amyloid levels." @default.
- W3048350830 created "2020-08-13" @default.
- W3048350830 creator A5001795846 @default.
- W3048350830 creator A5012342239 @default.
- W3048350830 creator A5019297725 @default.
- W3048350830 creator A5030911639 @default.
- W3048350830 creator A5034225628 @default.
- W3048350830 creator A5036718203 @default.
- W3048350830 creator A5059549486 @default.
- W3048350830 creator A5066821836 @default.
- W3048350830 creator A5068057129 @default.
- W3048350830 creator A5076723441 @default.
- W3048350830 creator A5090842068 @default.
- W3048350830 date "2020-12-01" @default.
- W3048350830 modified "2023-10-17" @default.
- W3048350830 title "Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment" @default.
- W3048350830 cites W1982813521 @default.
- W3048350830 cites W1997074193 @default.
- W3048350830 cites W2004344916 @default.
- W3048350830 cites W2024155268 @default.
- W3048350830 cites W2031489026 @default.
- W3048350830 cites W2049932209 @default.
- W3048350830 cites W2066358461 @default.
- W3048350830 cites W2075688280 @default.
- W3048350830 cites W2084531845 @default.
- W3048350830 cites W2088503700 @default.
- W3048350830 cites W2103346709 @default.
- W3048350830 cites W2112579276 @default.
- W3048350830 cites W2115017507 @default.
- W3048350830 cites W2120450971 @default.
- W3048350830 cites W2129497119 @default.
- W3048350830 cites W2148083007 @default.
- W3048350830 cites W2155783555 @default.
- W3048350830 cites W2171250577 @default.
- W3048350830 cites W2214656395 @default.
- W3048350830 cites W2309442902 @default.
- W3048350830 cites W2510361771 @default.
- W3048350830 cites W2557611948 @default.
- W3048350830 cites W2582524520 @default.
- W3048350830 cites W2593529118 @default.
- W3048350830 cites W2626001339 @default.
- W3048350830 cites W2766130492 @default.
- W3048350830 cites W2766763626 @default.
- W3048350830 cites W2883566515 @default.
- W3048350830 cites W2905929083 @default.
- W3048350830 cites W2915186472 @default.
- W3048350830 cites W2921161734 @default.
- W3048350830 cites W2942792614 @default.
- W3048350830 cites W3005636588 @default.
- W3048350830 cites W3005835533 @default.
- W3048350830 cites W3014487247 @default.
- W3048350830 cites W4240687639 @default.
- W3048350830 cites W4245386160 @default.
- W3048350830 cites W4252683201 @default.
- W3048350830 doi "https://doi.org/10.1001/jamaneurol.2020.2734" @default.
- W3048350830 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7418046" @default.
- W3048350830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32777010" @default.
- W3048350830 hasPublicationYear "2020" @default.
- W3048350830 type Work @default.
- W3048350830 sameAs 3048350830 @default.
- W3048350830 citedByCount "39" @default.
- W3048350830 countsByYear W30483508302021 @default.
- W3048350830 countsByYear W30483508302022 @default.
- W3048350830 countsByYear W30483508302023 @default.
- W3048350830 crossrefType "journal-article" @default.
- W3048350830 hasAuthorship W3048350830A5001795846 @default.
- W3048350830 hasAuthorship W3048350830A5012342239 @default.
- W3048350830 hasAuthorship W3048350830A5019297725 @default.
- W3048350830 hasAuthorship W3048350830A5030911639 @default.
- W3048350830 hasAuthorship W3048350830A5034225628 @default.
- W3048350830 hasAuthorship W3048350830A5036718203 @default.
- W3048350830 hasAuthorship W3048350830A5059549486 @default.
- W3048350830 hasAuthorship W3048350830A5066821836 @default.
- W3048350830 hasAuthorship W3048350830A5068057129 @default.
- W3048350830 hasAuthorship W3048350830A5076723441 @default.
- W3048350830 hasAuthorship W3048350830A5090842068 @default.
- W3048350830 hasBestOaLocation W30483508301 @default.
- W3048350830 hasConcept C118552586 @default.
- W3048350830 hasConcept C126322002 @default.
- W3048350830 hasConcept C15744967 @default.
- W3048350830 hasConcept C169900460 @default.
- W3048350830 hasConcept C185592680 @default.
- W3048350830 hasConcept C23131810 @default.
- W3048350830 hasConcept C2776760841 @default.
- W3048350830 hasConcept C2781197716 @default.
- W3048350830 hasConcept C3019858935 @default.
- W3048350830 hasConcept C535046627 @default.
- W3048350830 hasConcept C55493867 @default.
- W3048350830 hasConcept C558461103 @default.
- W3048350830 hasConcept C70410870 @default.
- W3048350830 hasConcept C71924100 @default.
- W3048350830 hasConcept C72563966 @default.
- W3048350830 hasConceptScore W3048350830C118552586 @default.
- W3048350830 hasConceptScore W3048350830C126322002 @default.
- W3048350830 hasConceptScore W3048350830C15744967 @default.
- W3048350830 hasConceptScore W3048350830C169900460 @default.
- W3048350830 hasConceptScore W3048350830C185592680 @default.
- W3048350830 hasConceptScore W3048350830C23131810 @default.